TCMD - tactilemedical.com Debt to Book Capitalization Ratio

Corporate company logo of Tactile Systems Technology Inc. (TCMD)

Risks for Tactile Systems Technology (TCMD) are linked to the revision of Medicare payments and sales staff costs, with the metric standing at 0.06. The price action chart reflects the dynamics of the lymphedema systems manufacturer's shares. Stability is ensured by partnerships with numerous insurance companies and clinics. Despite its narrow specialization, Tactile Systems Technology (TCMD) leads the US market, generating revenue from the regular sale of ancillary materials.

Tactile Systems Technology, Inc. - TCMD Debts to Book Capitalization (period 07/04/2022 - 10/27/2026)
Flagship merchandise of Tactile Systems Technology, Inc.

This indicator reflects the proportion of borrowed funds relative to the value of net assets, allowing a conservative investor to assess the real financial stability and the degree of the business's dependence on creditors. By analyzing the dynamics of debt obligations to balance sheet capital, one can determine the margin of safety for Tactile Systems Technology (TCMD) given that revenue depends on insurance company decisions regarding the reimbursement of lymphedema therapy costs.

Competitors of Tactile Systems Technology

DXCM: Debts to Book Capitalization|penumbrainc.com - Debts to Book Value|Debt to Book Capitalization Ratio Novanta (NOVT)|HAE - Debt to Net Assets Ratio|INSP: Debts to Book Capitalization|PRCT (Procept) - Debts to Book Capitalization|Debt to Book Capitalization Ratio CONMED Corporation CNMD|Debts to Book Capitalization Ratio pulsebiosciences.com|InMode - Debts to Book Capitalization|Debts to Book Value Picard Medical Corp PMI|Debt to Book Value SRDX (Surmodics Corp)|SENS - Debts to Book Capitalization|Debt to Book Value NeuroPace, Inc. NPCE|SNWV - Debt to Book Capital|Outset Medical - Debts to Book Capitalization|Electromed (ELMD) - Debts to Net Assets|Debts to Book Capitalization LNSR|Debt to Book Value AVITA Medical Inc (RCEL)|Profound Medical Corp. (PROF) - Debt to Book Value|Debt to Net Assets Ratio BDMD (bairdmed.com)|EDAP TMS - Debt to Book Capitalization Ratio|Debt to Book Value Apyx Medical Corp APYX|ICCM (IceCure Medical, Ltd.) - Debts to Book Capitalization|LUNG - Debts to Book Value|Debts to Book Capitalization telabio.com|CytoSorbents Corporation (CTSO) - Debt to Book Value Ratio|SRTS: Debts to Book Capitalization|Debts to Net Assets Zynex Medical|Debts to Book Capitalization ECOR (electroCore, Inc.)|Debt to Book Value vicarioussurgical.com (RBOT)|Debts to Book Capitalization IINN (Inspira Technologies)|seastarmedical.com - Debts to Book Capitalization|IRIX - Debt to Book Capitalization Ratio|Intelligent Bio Solutions (INBS) - Debt to Book Capitalization Ratio|Debt to Book Value beyondair.net XAIR|Profusa, Inc (PFSA) - Debt to Net Assets Ratio|Debts to Book Capitalization SSKN (STRATA Skin Sciences Inc.)|Debts to Book Value GCTK|NAOV: Debt to Book Capitalization Ratio|Debt to Net Assets Venus Concept Inc VERO|Debt to Book Value NUWE (CHF Solutions)|Debts to Book Capitalization Aethlon Medical Corp AEMD|Debts to Book Capitalization ASXC (TransEnterix)|AVGR: Debts to Net Assets|Debt to Book Capitalization Ratio Biosig Technologies (BSGM)|CUTR (Cutera Inc.) - Debts to Book Capitalization Ratio|Debt to Book Capitalization Ratio KNW|Debt to Book Value Inari Medical Corp|Nevro Corp. - Debts to Book Capitalization|Debts to Book Value RSLS (reshapelifesciences.com)|SILK - Debt to Book Capitalization Ratio